EXPAREL liposomal 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification
Decision 
Information 
1 issued on 
Issued2 / 
affected3  
amended 
on 
II/0005 
Extension of indication to include treatment of 
15/09/2022 
07/11/2022 
SmPC and PL 
Please refer to Scientific Discussion EXPAREL liposomal 
children aged 6 and older as a field block for 
treatment of somatic post-operative pain from small- 
to medium-sized surgical wounds for EXPAREL 
liposomal; as a consequence, sections 4.1,4.2, 4.4, 
4.5, 4.8, 5.1, 5.2 and 6.6 of the SmPC are updated. 
EMEA/H/C/004586/II/0005. 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
The Package Leaflet is updated in accordance. 
Version 1.1 of the RMP has also been submitted. 
The variation leads to amendments to the Summary 
of Product Characteristics and Package Leaflet and to 
the Risk Management Plan (RMP). 
C.I.6.a - Change(s) to therapeutic indication(s) - 
Addition of a new therapeutic indication or 
modification of an approved one 
PSUSA/10889
Periodic Safety Update EU Single assessment - 
05/05/2022 
n/a 
PRAC Recommendation - maintenance 
/202110 
bupivacaine (liposomal formulations) 
IB/0009/G 
This was an application for a group of variations. 
19/04/2022 
n/a 
B.II.c.1.a - Change in the specification parameters 
and/or limits of an excipient - Tightening of 
specification limits 
B.II.c.1.a - Change in the specification parameters 
and/or limits of an excipient - Tightening of 
specification limits 
B.II.c.1.z - Change in the specification parameters 
and/or limits of an excipient - Other variation 
B.I.b.1.z - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Other variation 
B.I.b.1.z - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Other variation 
B.I.b.1.b - Change in the specification parameters 
and/or limits of an AS, starting 
Page 2/5 
 
 
 
 
 
 
 
 
 
 
 
 
material/intermediate/reagent - Tightening of 
specification limits 
B.I.b.1.b - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Tightening of 
specification limits 
B.II.e.7.a - Change in supplier of packaging 
components or devices (when mentioned in the 
dossier) - Deletion of a supplier 
IB/0006 
B.II.c.z - Change in control of excipients in the 
07/12/2021 
n/a 
Finished Product - Other variation 
IA/0007/G 
This was an application for a group of variations. 
22/11/2021 
n/a 
B.II.c.1.a - Change in the specification parameters 
and/or limits of an excipient - Tightening of 
specification limits 
A.z - Administrative change - Other variation 
B.II.d.2.a - Change in test procedure for the finished 
product - Minor changes to an approved test 
procedure 
B.II.c.1.a - Change in the specification parameters 
and/or limits of an excipient - Tightening of 
specification limits 
B.I.b.1.b - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Tightening of 
specification limits 
B.II.c.1.a - Change in the specification parameters 
and/or limits of an excipient - Tightening of 
Page 3/5 
 
 
 
 
 
 
 
 
 
 
 
 
specification limits 
B.I.b.1.d - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Deletion of a non-
significant specification parameter (e.g. deletion of 
an obsolete parameter) 
B.I.b.1.b - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Tightening of 
specification limits 
B.I.b.1.d - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Deletion of a non-
significant specification parameter (e.g. deletion of 
an obsolete parameter) 
B.II.c.1.c - Change in the specification parameters 
and/or limits of an excipient - Deletion of a non-
significant specification parameter (e.g. deletion of 
an obsolete parameter) 
IB/0004/G 
This was an application for a group of variations. 
29/10/2021 
n/a 
B.II.c.2.a - Change in test procedure for an excipient 
- Minor changes to an approved test procedure 
PSUSA/10889
Periodic Safety Update EU Single assessment - 
28/10/2021 
n/a 
PRAC Recommendation - maintenance 
/202104 
bupivacaine (liposomal formulations) 
IB/0002/G 
This was an application for a group of variations. 
13/07/2021 
n/a 
B.II.c.1.a - Change in the specification parameters 
Page 4/5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
and/or limits of an excipient - Tightening of 
specification limits 
B.II.c.2.a - Change in test procedure for an excipient 
- Minor changes to an approved test procedure 
Page 5/5 
 
 
 
 
 
 
 
